This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Several impressions on the surface of the liver accommodate the various adjacent structures and organs. Underneath the right lobe and to the right of the gallbladder fossa are two impressions, one behind the other and separated by a ridge. The one in front is a shallow colic impression, formed by the hepatic flexure and the one behind is a deeper renal impression accommodating part of the right kidney and part of the suprarenal gland. The suprarenal impression is a small, triangular, depressed area on the liver. It is located close to the right of the fossa, between the bare area and the caudate lobe, and immediately above the renal impression. The greater part of the suprarenal impression is devoid of peritoneum and it lodges the right suprarenal gland. Medial to the renal impression is a third and slightly marked impression, lying between it and the neck of the gall bladder. This is caused by the descending portion of the duodenum, and is known as the duodenal impression. The inferior surface of the left lobe of the liver presents behind and to the left of the gastric impression. This is moulded over the upper front surface of the stomach, and to the right of this is a rounded eminence, the tuber omentale, which fits into the concavity of the lesser curvature of the stomach and lies in front of the anterior layer of the lesser omentum.
hydrogenation Any chemical reaction between molecular hydrogen (H2) and another chemical species, typically resulting in the reduction or saturation of the other species by the addition of one or more pairs of hydrogen atoms to a compound or element. The presence of a catalyst is usually required for hydrogenation reactions to occur; non-catalytic hydrogenation takes place only at extreme temperatures.
=== June === 1 June – A bioRxiv preprint reports the first use of base editing to alter the genome of early human embryos. Researchers at Columbia University used the technique to introduce precise single-letter DNA changes without the large chromosomal alterations previously associated with double-strand-break CRISPR gene editing, while noting that the approach remains far from clinical use and raises ethical questions over human germline engineering. 3 June – A report by the United Nations University Institute for Water, Environment and Health estimates that global data centre electricity consumption could reach 945 TWh by 2030, driven partly by growing demand for artificial intelligence, with associated water use rising to 9.3 trillion litres and carbon dioxide emissions to 399 million tonnes. 4 June – Chinese researchers discover the two-state model of liquid water theorizing that water is composed of two distinct and interconvertible local structures at the high and low density phase boundary. 5 June – Researchers at the University of Cambridge and DIOSynVax report the first human clinical trial of a vaccine whose active component was designed entirely by computer simulations. The candidate pan-Sarbecovirus vaccine, pEVAC-PS, uses a machine-learning-designed "super-antigen"; a phase I trial in 39 healthy volunteers finds it safe and able to trigger immune responses to SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses.
Sources: en.wikipedia.org
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
=== Blood Loss === In response to significant blood loss, either acute (e.g., trauma or surgery) or chronic (e.g., gastrointestinal bleeding), the bone marrow increases production to replace lost red blood cells. This results in an increased reticulocyte count, as new immature cells are released and make up a larger proportion of the blood volume.
== History and synthesis == DMF was first obtained in 1893 by the French chemist Albert Verley (1867–1959), by distilling a mixture of dimethylamine hydrochloride and potassium formate. It is now industrially manufactured by combining methyl formate and dimethylamine or by reaction of dimethylamine with carbon monoxide. Although currently impractical, DMF can be prepared from supercritical carbon dioxide using ruthenium-based catalysts.
The Bradford assay, a colorimetric protein assay, is based on an absorbance shift of the dye Coomassie brilliant blue G-250. The Coomassie brilliant blue G-250 dye exists in three forms: anionic (blue), neutral (green), and cationic (red). Under acidic conditions, the dye is red; when it is deprotonated, the red form of the dye is converted into its blue form, which can bind to the protein being assayed. If there is no protein present, then the solution will remain brown. Dye-protein interactions are driven by electrostatic interactions between positively charged arginine (and to a lesser extent, lysine and histidine) and the deprotonated negatively charged sulfonate groups on the dye, as well as hydrophobic interactions with the aromatic amino acids (tryptophan, tyrosine, phenylalanine). Binding of the dye to the protein stabilizes the anionic form of the dye, which can be detected colorimetrically by a shift from 465 nm to 595 nm. The cationic (unbound) form is red and has an absorption spectrum maximum at 465 nm, whereas the anionic bound form has an absorption spectrum maximum at 595 nm. The increase of absorbance at 595 nm is proportional to the amount of bound dye, and thus to the amount (concentration) of protein present in the sample. Unlike other protein assays, the Bradford protein assay is less susceptible to interference by various chemical compounds such as sodium, potassium or even carbohydrates like sucrose, that may be present in protein samples. An exception of note is elevated concentrations of detergent.
Sources: en.wikipedia.org
The English word for tanning is from the medieval Latin verb tannāre, from the noun tannum (oak bark). This term may be derived from a Celtic word related to the Proto-Indo-European *dʰonu meaning 'fir tree'. (The same root is the source for Old High German tanna meaning 'fir', related to modern German Tannenbaum). Hide clothing, footwear, and shelters have been used since the Paleolithic, with evidence of leather working dated to approximately 400,000 years ago; leather working tools from this period being found at Hoxne, England dating to about 400,000 years ago. Extant vegetable oil tanned leather footwear, from the neolithic (c. 5,500-year-old), has been found in Areni-1 cave, of Vayots Dzor province of Armenia and on the remains of the Ötzi corpse, found on the Austria-Italy border. Ancient civilizations used leather for waterskins, bags, harnesses and tack, boats, armour, quivers, scabbards, boots, and sandals. Tanning was being carried out by the inhabitants of Mehrgarh in Pakistan between 7000 and 3300 BCE. Around 2500 BCE, the Sumerians began using leather, affixed by copper studs, on chariot wheels. The process of tanning was also used for boats and fishing vessels: ropes, nets, and sails were tanned using tree bark. Formerly, tanning was considered a noxious or "odoriferous trade" and relegated to the outskirts of town, among the poor. Tanning by ancient methods is so foul-smelling that tanneries are still isolated from those towns today where the old methods are used. Skins typically arrived at the tannery dried stiff and dirty with soil and gore.
=== Wound repair versus regeneration === An injury is an interruption of morphology and/or functionality of a given tissue. After injury, structural tissue heals with incomplete or complete regeneration. Tissue without an interruption to the morphology almost always completely regenerates. An example of complete regeneration without an interruption of the morphology is non-injured tissue, such as skin. Non-injured skin has a continued replacement and regeneration of cells which always results in complete regeneration. There is a subtle distinction between 'repair' and 'regeneration'. Repair means incomplete regeneration. Repair or incomplete regeneration, refers to the physiologic adaptation of an organ after injury in an effort to re-establish continuity without regards to exact replacement of lost/damaged tissue. True tissue regeneration or complete regeneration, refers to the replacement of lost/damaged tissue with an 'exact' copy, such that both morphology and functionality are completely restored. Though after injury mammals can completely regenerate spontaneously, they usually do not completely regenerate. An example of a tissue regenerating completely after an interruption of morphology is the endometrium; the endometrium after the process of breakdown via the menstruation cycle heals with complete regeneration. In some instances, after a tissue breakdown, such as in skin, a regeneration closer to complete regeneration may be induced by the use of biodegradable (collagen-glycoaminoglycan) scaffolds.
== Factors determining protein half-life == Some key factors that determine overall rate include protein half-life, pH, and temperature. Protein half-life helps determine the overall rate as this designates the first step in protein catabolism. Depending on whether this step is short or long will influence the rest of the metabolic process. One key component in determining the protein half-life is based on the N-end rule. This states that the amino acid present at the N-terminus of a protein helps determine the protein's half-life.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.